Member Exclusive News

The week in industry: NICE rejects KEYTRUDA® as treatment for head and neck cancer

This week: an advanced prostate cancer treatment granted US FDA priority review and a partnership announced that will leverage AI and computational biophysics to develop novel cancer therapies.

Go to the profile of RxNet
Jan 16, 2020

Please sign in or register for FREE

No comments yet.